Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,000Price:--
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20,000Price:$91.26
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:20,000Price:$63.10
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,000Price:--
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20,000Price:$90.99
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:20,000Price:$63.10
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Burkhart ErinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,286Price:$90.00
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Davis George EricOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,602Price:$88.34
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Slamon DennisOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-10,000Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Slamon DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-9,510Price:$83.81
Filings by filing date
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,000Price:--
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,000Price:--
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20,000Price:$91.26
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:20,000Price:$63.10
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20,000Price:$90.99
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:20,000Price:$63.10
-
Apr 10, 2024 (filed on Apr 12, 2024)Insider Name:Burkhart ErinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,286Price:$90.00
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Davis George EricOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,602Price:$88.34
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Slamon DennisOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-10,000Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Slamon DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-9,510Price:$83.81
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 105 Digital Dr NOVATO CA 94949-8703 |
Tel: | N/A |
Website: | https://www.biomarin.com |
IR: | See website |
Key People | ||
Alexander Hardy President, Chief Executive Officer, Director | Brian R. Mueller Chief Financial Officer, Executive Vice President - Finance | Henry J. Fuchs President - Worldwide Research and Development |
C. Greg Guyer Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer | G. Eric Davis Executive Vice President, Secretary, Chief Legal Officer | Jeffrey Robert Ajer Executive Vice President, Chief Commercial Officer |
Cristin Hubbard Executive Vice President, Chief Commercial Officer | Erin Burkhart Group Vice President, Chief Accounting Officer |
Business Overview |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease. |
Financial Overview |
For the fiscal year ended 31 December 2023, Biomarin Pharmaceutical Inc revenues increased 15% to $2.42B. Net income increased 18% to $167.6M. Revenues reflect Voxzogo segment increase from $169.1M to $469.9M, Palynziq1 segment increase of 19% to $303.9M, Rest of the world segment increase of 50% to $468.2M, United States segment increase of 13% to $771.3M. Net income benefited from Interest Income increase from $18M to $58.3M (income). |
Employees: | 3,401 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $16,996M as of Dec 31, 2023 |
Annual revenue (TTM): | $2,419M as of Dec 31, 2023 |
EBITDA (TTM): | $262.48M as of Dec 31, 2023 |
Net annual income (TTM): | $167.65M as of Dec 31, 2023 |
Free cash flow (TTM): | $51.65M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $13.38M as of Dec 31, 2023 |
Shares outstanding: | 189,775,040 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |